EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Case Series of the Combination of Voclosporin and Belimumab Treatment of Lupus Nephritis

Homa Timlin, Abbal Koirala, Duvuru Geetha

Glomerular Diseases · 30.04.2026 · 6 (1) · 208-215

DOI: 10.1159/000552239 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Glomerular Diseases, online erschienen am 30.04.2026. Verfasst von Homa Timlin und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD, USA. Die Arbeit nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Lupus nephritis (LN) remains challenging with high treatment failure and relapse rates. Current therapies often fail to achieve sustained renal remission. The objective of this research was to assess the safety and clinical effectiveness of dual therapy using voclosporin and belimumab in individuals with LN confirmed via kidney biopsy.

Methods

Retrospective case series of 16 female patients (median age 36) with kidney biopsy-proven LN treated with voclosporin (15.8–23.7 mg BID) plus belimumab (200 mg SC weekly/IV) between 2012 and 2025 in routine clinical practice. Baseline was defined as the laboratory value closest to the first kidney biopsy. Longitudinal data for urine protein-to-creatinine ratio (UPCR), serum creatinine, C3/C4 complement, and anti-dsDNA antibodies were analyzed using the Wilcoxon signed-rank test.

Results

Initiation of voclosporin and belimumab was associated with a marked reduction in proteinuria, with median UPCR declining from 2.175 g/g to 0.082 g/g and remaining low at final follow-up (0.131 g/g; all p ≤ 0.0005). Serologic markers improved concurrently, with increases in complement levels (C3 65.0–109.5, C4 6.5–20.5) and a decline in median anti-dsDNA (51.5–12.0). 62.5% of patients tapered corticosteroids to ≤5 mg/day or discontinued them, while serum creatinine increased modestly from 0.77 to 0.89 mg/dL.

Conclusions

The combination of voclosporin and belimumab is highly effective in inducing rapid and sustained renal remission and facilitating a significant reduction in corticosteroid dose in patients with LN.

Schlagwörter

Stichwörter der Autor:innen

BelimumabLupus nephritisMycophenolate mofetilVoclosporin

Autor:innen und Institutionen

  • Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
  • Division of Nephrology, Johns Hopkins School of Medicine, Baltimore, MD, USA.

Zitieren

APA

Timlin, H., Koirala, A., & Geetha, D. (2026). Case Series of the Combination of Voclosporin and Belimumab Treatment of Lupus Nephritis. Glomerular Diseases, 6(1), 208-215. https://doi.org/10.1159/000552239

Vancouver

Timlin H, Koirala A, Geetha D. Case Series of the Combination of Voclosporin and Belimumab Treatment of Lupus Nephritis. Glomerular Diseases. 2026;6(1):208-215. doi:10.1159/000552239

BibTeX
@article{Timlin2026,
  author = {Timlin, Homa and Koirala, Abbal and Geetha, Duvuru},
  title = {Case Series of the Combination of Voclosporin and Belimumab Treatment of Lupus Nephritis},
  journal = {Glomerular Diseases},
  year = {2026},
  volume = {6},
  number = {1},
  pages = {208--215},
  doi = {10.1159/000552239}
}
Kostenlos starten →